DELONIX BIOWORKS

Leading biotech in pathogen genome engineering

specializing in bacterial vaccine innovation

We are driving the transformation of bacterial vaccine development from empirical approaches to rational design

16⁺

Pathogens Genome
Engineering

Genetically Engineered
Vaccine Platforms

Innovative Bacterial
Vaccine Pipelines

40⁺

Highly Qualified
Employees

5400⁺_m²

State-of-the-Art
Facilities

Last Update September 2026

Technology

Proprietary pathogenic bacteria genome editing platform; one-stop solution for bacterial vaccine development.

Proprietary engineered OMV technology platform, enables next-generation OMV vaccine development with better efficacy, safety and lower costs.

Pipeline

Partnership

News